Onpharma Launches First Solana Equity Token Offering for a Real Business

A dental technology company has put its shares on Solana through a Regulation S offering, and the UK adviser on the deal hints at where private capital formation is heading.

Something quietly significant happened this week. First Block, a digital securities and tokenisation infrastructure company, worked with Onpharma Company and the UK advisory firm Crito Capital to launch what they describe as the first Solana based security token offering for an established operating business.

Not a fund. Not a property. A real company with customers, revenue and a product on the market.

Onpharma is not a cryptoasset venture. It makes dental technology. Its Onset EZ Pen buffers local anaesthetic so injections work faster and hurt less, the kind of unglamorous, genuinely useful product that rarely makes headlines in digital assets. That is exactly why this matters. The offering takes the equity of a working business and issues it as tokens, settling on Solana, inside existing United States securities law.

The raise is structured as a Regulation S offering, which means it is aimed at investors outside the United States. That keeps it within a well understood exemption while using blockchain rails to handle settlement and distribution. Atomic settlement, programmable ownership and digital distribution do the operational work that traditional private placements hand to lawyers, registrars and weeks of paperwork. The legal certainty is old. The plumbing is new.

There is a British thread worth pulling. The adviser steering the structuring is Crito Capital, a UK firm. So while the issuer sits in the United States and the investors sit offshore, a good deal of the thinking behind the deal is homegrown. The UK has spent the past year building the rules for exactly this kind of activity, from the FCA's incoming cryptoasset regime to the PISCES framework for trading private company shares. Deals like this are where a rulebook meets a real cap table.

Strip away the Solana branding and the story is about who gets to own a piece of a private company, and how easily. For most of modern history, owning equity in a business like Onpharma meant being in the room. A broker, a fund, a lawyer, a minimum cheque size that quietly excluded almost everyone. Tokenised equity does not erase those gates overnight. But it lowers the cost of issuing, splitting and settling ownership, and that changes the economics of who an issuer can afford to have on the register.

A sceptical reading deserves space too. One Regulation S offering on Solana is not proof that private markets have been rebuilt. Liquidity for tokens like these is still thin.

Secondary trading depends on venues that are only now maturing. And calling something the first is a marketing instinct as much as a factual claim. None of that is fatal. It is simply the difference between a milestone and a finished system.

For founders, the signal sits in the structure rather than the ticker. A business that does not need a traditional venture round can still gain from issuing equity that is cheap to administer and capable of reaching a wider, qualified investor base. Pair that with the secondary trading frameworks now appearing in the UK and elsewhere, and an alternative path comes into view. Raise incrementally, keep control, give early backers a route to liquidity without forcing a sale of the whole company. That is the real prize, and it is bigger than any single deal.

Onpharma will not change dentistry by tokenising its shares. But the model behind its raise points at something founders everywhere should be watching. The architecture of ownership is being rebuilt in public, one unglamorous company at a time.

Key Takeaways

• First Block, Onpharma Company and UK adviser Crito Capital have launched what they call the first Solana based security token offering for an established operating business.

• The deal uses a Regulation S structure aimed at non US investors, combining a familiar securities exemption with blockchain settlement and distribution.

• The significance is the asset type. This is real operating company equity onchain, not a fund or a property wrapper.

• For founders, the model points towards cheaper issuance, a wider qualified investor base and incremental raising that protects control.

• Caveats remain on secondary liquidity and the first label, so treat this as a milestone rather than a finished market.

---

Sources

• CryptoSlate, First Block, Onpharma Company, and Crito Capital Announce First Solana STO for U.S. Medical Device Business (17 Jun 2026)

• The Armchair Trader, Onpharma launches first Solana-based equity token offering (17 Jun 2026)

• The Daily Hodl, First Block, Onpharma Company and Crito Capital Announce First Solana STO for US Medical Device Business (17 Jun 2026)

Frequently asked questions

What is the Onpharma Solana equity token offering?

First Block, Onpharma Company and the UK advisory firm Crito Capital launched what they describe as the first Solana based security token offering for an established operating business. It issues the equity of a working dental technology company as tokens that settle on Solana.

What does Onpharma make?

Onpharma makes dental technology. Its Onset EZ Pen buffers local anaesthetic so injections work faster and hurt less.

Who is the Onpharma token offering aimed at?

The raise is structured as a Regulation S offering, which means it is aimed at investors outside the United States. It sits inside existing United States securities law while using blockchain rails for settlement and distribution.

What role did a UK firm play in the Onpharma deal?

Crito Capital, a UK advisory firm, steered the structuring of the offering. The issuer is in the United States and the investors are offshore.

Are tokenised equity offerings like Onpharma's easy to sell on?

Not yet. Liquidity for tokens like these is still thin, and secondary trading depends on venues that are only now maturing, so the deal is better seen as a milestone than a finished market.